<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029467</url>
  </required_header>
  <id_info>
    <org_study_id>LAUMCRH.YJ1.16/Jul/2019</org_study_id>
    <nct_id>NCT04029467</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine on the Duration of Pain Control in ESP Block for Breast Surgery</brief_title>
  <official_title>Addition of Dexmedetomidine to Ropivacaine for Ultrasound Guided Erector Spinae Block: Evaluation of Effect on Postoperative Pain After Breast Surgery: A Double-Blinded, Prospective, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lebanese American University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lebanese American University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing Partial or total mastectomy with axillary LN dissection will receive
      prior to induction of general anaesthesia ESP block at T4 level at the same side of the
      surgery. one group will receive ropivacaine 0.375% and the other will get ropivacaine 0.375%
      with dexmedetomidine 0.5mcg/kg as an adjuvant. time to first narcotic requirement will be
      documented and therefore an assessment of the duration of action of the block will be made
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Objective: Whether partial or complete, mastectomy with axillary lymph node
      dissection is a painful surgery. Acute postoperative pain management is challenging and
      crucial due to high chances of it transforming into chronic pain. Erector spinae plane (ESP)
      block has been shown to be effective in managing post mastectomy pain.Dai et al showed the
      effectiveness of dexmedetomidine in prolonging the duration of sensory block, motor block and
      analgesia when dexmedetomidine as an adjunct is added to ropivacaine in brachial plexus block
      (1). The aim of our study is to show the effectiveness of dexmedetomidine in prolonging the
      analgesic effect of ropivacaine when added to it in ESP block compared to using ropivacaine
      alone in patients undergoing mastectomy with axillary lymph node dissection, and to study its
      impact on postoperative opioid consumption.

      Methods: 44 American Society of Anesthesiologist (ASA) physical status classification class
      I, II and III will be randomly allocated to one of two groups, both receiving a single
      injection erector spinae plane block at T4 vertebral level using 20ml ropivacaine 0.375% 20
      minutes before the induction of anesthesia. The first group will receive 0.5mcg/kg of
      dexmedetomdine added to the ropivacaine solution. The control group will receive no
      dexmedetomidine.

      Postoperatively, patients in both groups will be receive acetaminophen 1g orally every 6
      hours and oxycodone 5 mg orally as needed every 6 hours if VAS is more than 4. Postoperative
      pain will be measured using Verbal Analogue Scale (VAS) at 0, 1, 2, 4, 6, 12, 18, and 24
      hours.

      Conclusion: This study will be the first of its kind to investigate the impact of adding
      dexmedetomidine as an adjunct to ropivacaine in prolonging the ESP block duration in patients
      undergoing mastectomy with axillary lymph node dissection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">January 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain assessment in the first 24 hours post operatively: VAS score</measure>
    <time_frame>24 hours</time_frame>
    <description>Pain will be assessed using the VAS score ranging from 0, indicating no pain at all, to 10, indicating the worst pain the patient has ever felt</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Mastectomy</condition>
  <condition>Axillary Lymph Node Dissection</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Precedex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants will receive an ESP block with 20 ml Ropivacaine 0.375% in the induction room 20 minutes before their operation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will receive an ESP block with 20 ml Ropivacaine 0.375% + 0.5mcg/kg dexmedetomidine in the induction room 20 minutes before their operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_label>Precedex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ASA class I, II and III patients

          2. Age range: 18-80 years old

          3. Elective partial or unilateral radical mastectomy with sentinel lymph node dissection

        Exclusion Criteria:

          1. Pregnant woman

          2. Bilateral mastectomy.

          3. Skin infection at the site of needle puncture

          4. Coagulopathy problems

          5. Allergy or contraindication to any of the study drugs

          6. Recent use of opioid drugs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Biologically female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yara Al Jalbout, MD</last_name>
    <phone>+9611200800</phone>
    <phone_ext>5226</phone_ext>
    <email>yara.aljalbout@lau.edu.lb</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanane Barakat, MD</last_name>
    <phone>+9611200800</phone>
    <phone_ext>5226</phone_ext>
    <email>hanane.barakat@laumcrh.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lebanese American University Medical Center-Rizk Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sami Rizk</last_name>
      <phone>+9611200800</phone>
      <phone_ext>6035</phone_ext>
      <email>sami.rizk@laumcrh.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lebanese American University</investigator_affiliation>
    <investigator_full_name>Yara Al Jalbout</investigator_full_name>
    <investigator_title>Clinical Instructor, Director Anaesthesiology Residency Program</investigator_title>
  </responsible_party>
  <keyword>ESP block</keyword>
  <keyword>erector spinae plane block</keyword>
  <keyword>mastectomy</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>pain</keyword>
  <keyword>breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

